Hemostasis and Thrombosis in Critically Ill Children

ABSTRACT

Patients in the pediatric intensive care unit (PICU) often suffer from a variety of pathophysiologic conditions that are associated with abnormal hemostasis. Bleeding is a major complication of any surgery or trauma, thus patients with inherited or acquired coagulopathies or those experiencing massive trauma or undergoing major (especially cardiac) operations present a special challenge to the ICU experts as well as to the hematologist. Awareness of thromboembolic events in the pediatric population has been increasing in the past few years mainly due to improvement in diagnostic tools, advances in new therapy and procedures, together with an increased index of suspicion. Young infants are at greater risk for either bleeding or thromboembolic events, due to lower concentration of vitamin K–dependent procoagulant clotting factors, reduced thrombin potential, and altered fibrinolytic pathway with low levels of the coagulation inhibitors. The combination of infection, hypotension, acidosis, and release of activated substances, such as tumor necrosis factor, is common after severe trauma or in seriously ill ICU patients and often leads to disseminated intravascular coagulation, which may be complicated either by bleeding or thrombosis. The conditions, risk factors, and therapeutic options available for critically ill PICU patients are discussed in this review.

KEYWORDS

Bleeding - thrombosis - pediatric - rFVIIa - DIC

REFERENCES

• 1 Andrew M, David M, Adams M et al.. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE.  Blood. 1994;  83 1251-1257
• 2 Monagle P, Adams M, Mahoney M et al.. Outcome of pediatric thromboembolic disease: a report from the Canadian Child-hood Thrombophilia Registry.  Pediatr Res. 2000;  47 763-766
• 3 Van Ommen C H, Heijboer H, Büller H R, Hirasing R A, Heijmans H SA, Peters M. Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands.  J Pediatr. 2001;  139 676-681
• 4 Tormene D, Gavasso S, Rossetto V, Simioni P. Thrombosis and thrombophilia in children: a systematic review.  Semin Thromb Hemost. 2006;  32 724-728
• 5 Thornburg C A, Pipe S. Neonatal thromboembolic emergencies.  Semin Fetal Neonatal Med. 2006;  11 198-206
• 6 Beardsley D S. Venous thromboembolism in the neonatal period.  Semin Perinatol. 2007;  31 250-253
• 7 Williams M D, Chalmers E A, Gibson B E. The investigation and management of neonatal haemostasis and thrombosis.  Br J Haematol. 2002;  119 295-309
• 8 Andrew M, Paes B, Milner R et al.. Development of the human coagulation system in the full-term infant.  Blood. 1987;  70 165-172
• 9 McEwan A. Aspects of bleeding after cardiac surgery in children.  Paediatr Anaesth. 2007;  17 1126-1133
• 10 Martinowitz U, Michaelson M. On behalf of the Israeli Multidisciplinary rFVIIa Task Force. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force.  J Thromb Haemost. 2005;  3 640-648
• 11 Blajchman M A, Vamvakas E C. The continuing risk of transfusion transmitted of infections.  N Engl J Med. 2006;  355 1303-1305
• 12 Brohi K, Cohen M J, Devenport R A. Acute coagulopathy of trauma: mechanism, identification and effect.  Curr Opin Crit Care. 2007;  13 680-685
• 13 Bulutcu F S, Ozbek U, Polat B, Yalcin Y, Karaci A R, Bayindir O. Which may be effective to reduce blood loss after cardiac operations in cyanotic children: tranexamic acid, aprotinin or combination?.  Paediatr Anaesth. 2005;  15 41-46
• 14 Dietrich W, Ebell A, Busley R, Boulesteix A L. Aprotinin and anaphylaxis: analysis of 12,403 exposures to aprotinin in cardiac surgery.  Ann Thorac Surg. 2007;  84 1144-1150
• 15 Mangano D T, Tudor I C, Dietzel C. The risk associated with aprotinin in cardiac surgery.  N Engl J Med. 2006;  354 353-365
• 16 Khair K, Baker K, Mathias M, Burgess C, Leisner R. Intranasal desmopression (Octim): a safe and efficacious treatment option for children with bleeding disorders.  Haemophilia. 2007;  13 548-551
• 17 Das P, Carcao M, Hitzler J. DDAVP-induced hyponatremia in young children.  J Pediatr Hematol Oncol. 2005;  27 330-332
• 18 Guay J, DeMoerloose P, Lasne D. Minimizing perioperative blood loss and transfusions in children.  Can J Anaesth. 2006;  53(6 Suppl) S59-S67
• 19 Kjalke M, Johannessen M, Hedner U. Effect of recombinant factor VIIa (NovoSeven) on thrombocytopenia-like conditions in vitro .  Semin Hematol. 2001;  38 15-20
• 20 Galan A M, Tonda R, Pino M et al.. Increased local procoagulant action: a mechanism contributing to the favorable hemostatic effect of recombinant FVIIa in platelet disorder.  Transfusion. 2003;  43 885-892
• 21 Lisman T, Mosnier L O, Lambert T et al.. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A.  Blood. 2002;  99 175-179
• 22 Antovic J P, Antovic A. Does recombinant factor VIIa, apart from overall hemostasis, regulate TAFI dependent fibrinolysis? In vitro analysis using overall hemostasis potential (OHP) assay.  Thromb Haemost. 2003;  90 620-627
• 23 Mathew P, Young G. Recombinant factor VIIa in paediatric bleeding disorders—a 2006 review.  Haemophilia. 2006;  12 457-472
• 24 Levi M, Peters M, Buller H R. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review.  Crit Care Med. 2005;  33 883-890
• 25 Kolban M, Balachowska-Kosciolek I, Chmielnicki M. Recombinant coagulation factor VIIa—a novel haemostatic agent in scoliosis surgery?.  Eur Spine J. 2006;  15 944-952
• 26 Heisel M, Nagib M, Madsen L et al.. Use of recombinant factor VIIa (rFVIIa) to control intraoperative bleeding in pediatric brain tumor patients.  Pediatr Blood Cancer. 2004;  43 703-705
• 27 Almeida A M, Khair K, Hann I, Liesner R. The use of recombinant factor VIIa in children with inherited platelet function disorders.  Br J Haematol. 2003;  121 477-481
• 28 Chuansumrit A, Tangnararatchakit K, Lektakul Y et al.. The use of recombinant activated factor VII for controlling life-threatening bleeding in dengue shock syndrome.  Blood Coagul Fibrinolysis. 2004;  15 335-342
• 29 Pettersson M, Fischler B, Petrini P et al.. Recombinant FVIIa in children with liver disease.  Thromb Res. 2005;  116 185-197
• 30 Greisen G, Andreasen R B. Recombinant factor VIIa in preterm neonates with prolonged prothrombin time.  Blood Coagul Fibrinolysis. 2003;  14 117-120
• 31 Brown J B, Emerick K M, Brown D L et al.. Recombinant factor VIIa improves coagulopathy caused by liver failure.  J Pediatr Gastroenterol Nutr. 2003;  37 268-272
• 32 Tobias J D, Groeper K, Berkenbosch J W. Preliminary experience with the use of recombinant factor VIIa to treat coagulation disturbances in pediatric patients.  South Med J. 2003;  96 12-16
• 33 Markiewicz M, Kalicinski P, Kaminski A et al.. Acute coagulopathy after reperfusion of the liver graft in children: correction with recombinant activated factor VII.  Transplant Proc. 2003;  35 2318-2319
• 34 Tobias J D, Simsic J M, Weinstein S et al.. Recombinant factor VIIa to control excessive bleeding following surgery for congenital heart disease in pediatric patients.  J Intensive Care Med. 2004;  19 270-273
• 35 Pychynska-Pokorska M, Moll J J, Krajewski , Jarosik P. The use of recombinant coagulation factor VIIa in uncontrolled postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass.  Pediatr Crit Care Med. 2004;  5 246-250
• 36 Agarwal H S, Bennett J E, Churchwell K B et al.. Recombinant factor VII for postoperative bleeding in neonatal and pediatric cardiac surgery.  Ann Thorac Surg. 2007;  84 161-168
• 37 Veldman A, Neuhacuser C, Akintuerk H, Thul J, Schranz D, Michel-Behnke I. Recombinant factor VIIa in the treatment of persistant hemorrhage in pediatric patients on ECMO following surgery for congenital heart disease.  Paediatr Anaesth. 2007;  17 1176-1181
• 38 Monroe D M, Roberts H R. Mechanism of action of high-dose factor VIIa: points of agreement and disagreement.  Arterioscler Thromb Vasc Biol. 2003;  23 8-9
• 39 Hoffman M, Monroe D M. A cell-based model of hemostasis.  Thromb Haemost. 2001;  85 958-965
• 40 Abshire T C. Dose optimization of recombinant factor VIIa for control of mild to moderate bleeds in inhibitor patients: improved efficacy with higher dosing.  Semin Hematol. 2004;  41 3-7
• 41 O'Connell K A, Wood J J, Wise R P et al.. Thromboembolic adverse events after use of recombinant human coagulation factor IIa.  JAMA. 2006;  295 293-298
• 42 Mannucci P M, Levi M. Prevention and treatment of major blood loss.  N Engl J Med. 2007;  356 2301-2311
• 43 Levi M, Ten Cate H. Dissemination intravascular coagulation.  N Engl J Med. 1999;  341 586-592
• 44 Faust S N, Levin M, Harrison O B et al.. Dysfunction of endothelial protein C activation in severe meningococcal sepsis.  N Engl J Med. 2001;  345 408-416
• 45 Levi M, De jonge E, Van der Poll T. Sepsis and disseminated intravascular coagulation.  J Thromb Thrombolysis. 2003;  16 43-47
• 46 Levi M. Disseminated intravascular coagulation—What's new?.  Crit Care Clin. 2005;  21 449-467
• 47 Marti-Carvajal A, Salanti G, Cardona A F. Human recombinant activated protein for severe sepsis.  Cochrane Database Syst Rev. 2007;  (3) CD004388
• 48 Kylat R I, Ohlsson A. A recombinant human activated protein C for severe sepsis in neonates.  Cochrane Database Syst Rev. 2006;  (19) CD005385
• 49 Athale U H, Siciliano S A, Crowther M, Barr R D, Chan A K. Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease.  Br J Haematol. 2005;  129 803-810
• 50 Glaser D W, Medeiros D, Rollins N et al.. Catheter-related thrombosis in children with cancer.  J Pediatr. 2001;  138 255-259
• 51 Journeycake J M, Buchanan G R. Thrombotic complications of central venous catheters in children.  Curr Opin Hematol. 2003;  10 369-374
• 52 Dubois J, Rypens F, Garel L, David M, Lacroix J, Gauvin F. Incidence of deep vein thrombosis related to peripherally inserted central catheters in children and adolescents.  CMAJ. 2007;  177 1185-1190
• 53 Massicotte M P, Dix D, Monagle P, Adams M, Andrew M. Central venous catheter related thrombosis in children: analysis of the Canadian Registry of venous thromboembolic complications.  J Pediatr. 1998;  133 770-776
• 54 Ruud E, Holmstrøm H, Hopp E, Wesenberg F. Central line-associated venous late effects in children without prior history of thrombosis.  Acta Paediatr. 2006;  95 1060-1065
• 55 Hermansen M C, Hermansen M G. Intravascular catheter complications in the neonatal intensive care unit.  Clin Perinatol. 2005;  32 141-156
• 56 Albisetti M, Schmugge M, Haas R et al.. Arterial thromboembolic complications in critically ill children.  J Crit Care. 2005;  20 296-300
• 57 Monagle P, Newall F, Barnes C et al.. Arterial thromboembolic disease: a single-centre case series study.  J Paediatr Child Health. 2008;  44 28-32
• 58 Kirkham F, Sebire G, Steinlin M et al.. Arterial ischaemic stroke in children. Review of the literature and strategies for future stroke studies.  Thromb Haemost. 2004;  92 697-706
• 59 Goldenberg N A. Long-term outcomes of venous thrombosis in children.  Curr Opin Hematol. 2005;  12 370-376
• 60 Nowak-Göttl U, Junker R, Kreuz W et al.. Childhood Thrombophilia Study Group. Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors.  Blood. 2001;  97 858-862
• 61 Goldenberg N A, Knapp-Clevenger R, Manco-Johnson M J. Mountain States Regional Thrombophilia Group . Elevated plasma factor VIII and D-dimer levels as predictors of poor outcomes of thrombosis in children.  N Engl J Med. 2004;  351 1081-1088
• 62 Young G. Diagnosis and treatment of thrombosis in children: general principles.  Pediatr Blood Cancer. 2006;  46 540-546
• 63 Kotsakis A, Cook D, Griffith L et al.. Clinically important venous thromboembolism in pediatric critical care: a Canadian survery.  J Crit Care. 2005;  20 373-380
• 64 Grandas O H, Klar M, Goldman M H, Filston H C. Deep venous thrombosis in the pediatric trauma population: an unusual event: report of three cases.  Am Surg. 2000;  66 273-276
• 65 Athale U H, Chan A K. Thromboembolic complications in pediatric hematologic malignancies.  Semin Thromb Hemost. 2007;  33 416-426
• 66 Kajimoto H, Nakazawa M, Murasaki K et al.. Increased thrombogenesity in patients with cyanotic congenital heart disease.  Circ J. 2007;  71 948-953
• 67 Berkun Y, Padeh S, Barash J et al.. Antiphospholipid syndrome and recurrent thrombosis in children.  Arthritis Rheum. 2006;  55 850-885
• 68 Dentali F, Gianni M, Agnelli G, Ageno W. Association between inherited thrombophilic abnormalities and central venous catheter thrombosis in patients with cancer: a meta-analysis.  J Thromb Haemost. 2008;  6 70-75
• 69 Nowak-Gottl U, Kosch A, Schlegel N et al.. Thromboembolism in children.  Curr Opin Hematol. 2002;  9 448-453
• 70 Marlar R A, Neumann A. Neonatal purpura fulminans due to homozygous protein C or protein S deficiencies.  Semin Thromb Hemost. 1990;  16 299-309
• 71 Zimbelman J, Lefkowitz J, Schaeffer C et al.. Unusual complications of warfarin therapy: skin necrosis and priapism.  J Pediatr. 2000;  137 266-268
• 72 Pescatore S L. Clinical management of protein C deficiency.  Expert Opin Pharmacother. 2001;  2 431-439
• 73 Monagle P, Michelson A D, Bovill E, Andrew M. Antithrombotic therapy in children.  Chest. 2001;  119 344S-370S
• 74 Shah P S, Shah N. Heparin-bonded catheters for prolonging the patency of central venous catheters in children.  Cochrane Database Syst Rev. 2007;  (4) CD005983
• 75 Nowak-Göttl U, Bidingmayer C, Krümpel A et al.. Pharmacokinetics, efficacy, and safety of LMWHs in venous thrombosis and stroke in neonates, infants and children.  Br J Pharmacol. 2008;  153 1120-1127
• 76 Robinson A, Fellows K E, Bridges N D, Rome J J. Effectiveness of pharmacomechanical thrombolysis in infants and children.  Am J Cardiol. 2001;  87 496-499
• 77 Manco-Johnson M J, Grabowski E F, Hellgreen M et al.. Recommendations for tPA thrombolysis in children. On behalf of the Scientific Subcommittee on Perinatal and Pediatric Thrombosis of the Scientific and standardization Committee of the International Society of Thrombosis and Haemostasis.  Thromb Haemost. 2002;  88 157-158
• 78 Goldenberg N A, Durham J D, Knapp-Clevenger R, Manco-Johnson M J. A thrombolytic regimen for high-risk deep venous thrombosis may substantially reduce the risk of postthrombotic syndrome in children.  Blood. 2007;  110 45-53
• 79 Belvis R. Thrombolysis for acute stroke in pediatrics.  Stroke. 2007;  38 1722-1723
• 80 Young G, Tarantino M D, Whorley J. Pilot dose-finding and safety study of bivalirudin in infants < 6 months of age with thrombosis.  J Thromb Haemost. 2007;  5 1654-1659